专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09896472B2 Protected monomer and method of final deprotection for RNA synthesis 有权
公开(公告)号：US09896472B2
公开(公告)日：2018-02-20
申请号：US14853790
申请日：2015-09-14
申请人： Agilent Technologies, Inc.
发明人： Douglas J. Dellinger , Joel Myerson , Agnieszka Sierzchala , Geraldine F. Dellinger , Zoltan Timar
IPC分类号： C07H21/02 , C07H21/04 , C07H19/067 , C07H13/12 , A61K31/7125 , A61K31/712 , C07H19/00 , C07H19/167 , C07H21/00 , C07H23/00 , C07H1/00
CPC分类号： C07H19/067 , A61K31/712 , A61K31/7125 , C07H1/00 , C07H13/12 , C07H19/00 , C07H19/167 , C07H21/00 , C07H21/02 , C07H21/04 , C07H23/00 , Y02P20/55
摘要： A method of deprotecting a solid support bound polynucleotide includes the step of contacting the polynucleotide with a composition comprising a diamine under conditions sufficient to deprotect the 2′-protected ribonucleotide residue. The solid support bound polynucleotide has at least one 2′-protected ribonucleotide residue, which has the following structure: wherein BP is a protected or unprotected heterocycle; R12 is a protecting group selected from a hydrocarbyl, a substituted hydrocarbyl, an aryl, and a substituted aryl; X is O or S; and PG is a thionocarbamate protecting group.

2. 发明申请

US20170015697A1 SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE 审中-公开
标题翻译： TNF超家族受体的SPLICE切换寡核苷酸及其在治疗疾病中的应用
公开(公告)号：US20170015697A1
公开(公告)日：2017-01-19
申请号：US14746715
申请日：2015-06-22
申请人： ROCHE INNOVATION CENTER COPENHAGEN A/S
发明人： Henrik Orum , Peter L. Sazani
IPC分类号： C07H21/04
CPC分类号： C07H21/04 , A61K38/00 , C07H19/00 , C07H21/02 , C07K14/7151 , C12N2799/025 , C12N2799/026 , Y02A50/463
摘要： The present invention relates to compositions and methods for preparing splice variants of TNFalpha receptor (TNFR) in vivo or in vitro, and the resulting TNFR protein variants. Such variants may be prepared by controlling the splicing of pre-mRNA molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 or 8 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 or 8 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has therapeutic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.
摘要翻译：本发明涉及用于在体内或体外制备TNFα受体（TNFR）的剪接变体的组合物和方法，以及所得的TNFR蛋白质变体。可以通过控制前mRNA分子的剪接和用剪接切换寡核苷酸或剪接切换寡聚体（SSO）调节蛋白质表达来制备这些变体。根据本发明的优选SSO靶向TNFR1（TNFRSF1A）或TNFR2（TNFRSF1A）前mRNA的外显子7或8，通常导致在部分或全部外显子7或8中包含缺失的TNFR变体的产生。发现针对外显子7的SSOs产生可溶形式的TNFR，其具有治疗炎性疾病的治疗益处。 SSO的特点是它们基本上无能力或不能招募RNaseH。

3. 发明申请

US20160348165A1 Methods And Compositions For Incorporating Nucleotides 有权
公开(公告)号：US20160348165A1
公开(公告)日：2016-12-01
申请号：US15144079
申请日：2016-05-02
申请人： INTELLIGENT BIOSYSTEMS, INC.
发明人： Steven Gordon , Jerzy Olejnik
IPC分类号： C12Q1/68 , G01N21/64 , G01N21/05
CPC分类号： C07H19/00 , C12Q1/6869 , C12Q1/6874 , C12Q2535/101 , G01N21/05 , G01N21/6428 , G01N21/645 , G01N2021/0346 , G01N2021/058 , G01N2021/6417 , G01N2021/6419 , G01N2021/6421 , G01N2021/6439 , G01N2021/6441 , G01N2021/6471 , G01N2201/062 , G01N2201/0627 , G01N2201/12
摘要： The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

4. 发明授权

US09399799B2 Methods and compositions for incorporating nucleotides 有权
公开(公告)号：US09399799B2
公开(公告)日：2016-07-26
申请号：US14518114
申请日：2014-10-20
申请人： Intelligent BioSystems Inc.
发明人： Steven Gordon , Jerzy Olejnik
IPC分类号： C07H19/00 , C12Q1/68 , G01N21/64 , G01N21/05 , G01N21/03
CPC分类号： C07H19/00 , C12Q1/6869 , C12Q1/6874 , C12Q2535/101 , G01N21/05 , G01N21/6428 , G01N21/645 , G01N2021/0346 , G01N2021/058 , G01N2021/6417 , G01N2021/6419 , G01N2021/6421 , G01N2021/6439 , G01N2021/6441 , G01N2021/6471 , G01N2201/062 , G01N2201/0627 , G01N2201/12
摘要： The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

5. 发明申请

US20160168187A1 A METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES 审中-公开
标题翻译：通过联合核心技术对体外核酸的特异性酶标技术的方法
公开(公告)号：US20160168187A1
公开(公告)日：2016-06-16
申请号：US14910203
申请日：2014-08-08
申请人： THE SCRIPPS RESEARCH INSTITUTE
发明人： Floyd E. ROMESBERG , Denis A. MALYSHEV , Lingjun LI , Thomas LAVERGNE , Zhengtao LI
IPC分类号： C07H19/24 , C12P19/34
CPC分类号： C07H19/24 , C07H19/00 , C07H21/00 , C12P19/34 , C12Q1/6832 , C12Q2525/117
摘要： Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.
摘要翻译：本文提供了在DNA聚合酶介导的DNA或RNA聚合酶介导的RNA转录的DNA聚合酶介导的复制期间，主要具有疏水性核碱基类似物的类似物的类似物，其形成非天然碱基对。以这种方式，可以以位点特异性方式将非天然核碱基引入寡核苷酸（单链或双链DNA或RNA），其中它们可以提供位点特异性切割，或者可以提供比经过官能化的反应性连接体通过与伯氨基反应或通过使用非天然核碱基连接体的炔基进行点击化学反应的载货试剂。

6. 发明授权

US09120774B2 Novobiocin analogues having modified sugar moieties 有权
标题翻译：具有改性糖部分的新生霉素类似物
公开(公告)号：US09120774B2
公开(公告)日：2015-09-01
申请号：US13202382
申请日：2010-02-19
申请人： Brian S. J. Blagg , Huiping Zhao , Alison Catherine Donnelly
发明人： Brian S. J. Blagg , Huiping Zhao , Alison Catherine Donnelly
IPC分类号： C07H17/06 , C07D407/12 , C07D487/14 , C07H19/00
CPC分类号： C07D407/12 , C07D487/14 , C07H19/00
摘要： The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer.
摘要翻译：该公开内容提供具有noviose替代物的新生儿素类似物，其可用作治疗癌症中的Hsp90抑制剂。

7. 发明授权

US08946188B2 Anti-microbial agents and uses thereof 有权
标题翻译：抗微生物剂及其用途
公开(公告)号：US08946188B2
公开(公告)日：2015-02-03
申请号：US13897807
申请日：2013-05-20
申请人： Sloan-Kettering Institute for Cancer Research , Cornell Research Foundation, Inc.
发明人： Derek Shieh Tan , Luis E. N. Quadri , Jae-Sang Ryu , Justin Scott Cisar , Julian Alberto Ferreras , Xuequan Lu
IPC分类号： A01N43/04 , A61K31/70 , C07H19/24 , C07H19/00 , C07H19/22
CPC分类号： C07H19/24 , C07H19/00 , C07H19/22
摘要： Many pathogens, including Mycobacterium tuberculosis and Yersinia pestis, rely on an iron acquisition system based on siderophores, secreted iron-chelating compounds with extremely high Fe(III) affinity. The compounds of the invention are inhibitors of domain salicylation enzymes, which catalyze the salicylation of an aroyl carrier protein (ArCP) domain to form a salicyl-ArCP domain thioester intermediate via a two-step reaction. The compounds include the intermediate mimic 5′-O—[N-(salicyl)sulfamoyl]-adenosine (salicyl-AMS) and analogs thereof. These compounds are inhibitors of the salicylate activity of MbtA, YbtE, PchD, and other domain salicylation enzymes involved in the biosynthesis of siderophores. Therefore, these compounds may be used in the treatment of infection caused by microorganisms which rely on siderphore-based iron acquisition systems. Pharmaceutical composition and methods of using these compounds to treat or prevent infection are also provided as well as methods of preparing the inventive compounds.
摘要翻译：许多病原体，包括结核分枝杆菌和鼠疫耶尔森氏菌，依赖于铁铁捕获系统，其基于铁载体，具有极高Fe（III）亲和力的分泌铁螯合化合物。本发明的化合物是结构域水解酶的抑制剂，其催化芳酰基载体蛋白（ArCP）结构域的水杨酸化以通过两步反应形成水杨酰-ArCP结构域的硫酯中间体。所述化合物包括中间体模拟5'-O- [N-（水杨基）氨磺酰基] - 腺苷（水杨基-AMS）及其类似物。这些化合物是参与铁载体生物合成的MbtA，YbtE，PchD和其他结构域水杨酸酶的水杨酸盐活性的抑制剂。因此，这些化合物可用于治疗由依赖于白藜芦醇的铁采集系统的微生物引起的感染。还提供了使用这些化合物治疗或预防感染的药物组合物和方法以及制备本发明化合物的方法。

8. 发明申请

US20140357849A1 SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE 审中-公开
标题翻译： TNF超家族受体的SPLICE切换寡核苷酸及其在治疗疾病中的应用
公开(公告)号：US20140357849A1
公开(公告)日：2014-12-04
申请号：US14057968
申请日：2013-10-18
申请人： SANTARIS PHARMA A/S
发明人： Henrik Orum , Peter L. Sazani
IPC分类号： C07H21/04
CPC分类号： C07H21/04 , A61K38/00 , C07H19/00 , C07H21/02 , C07K14/7151 , C12N2799/025 , C12N2799/026 , Y02A50/463
摘要： The present invention relates to compositions and methods for preparing splice variants of TNFalpha receptor (TNFR) in vivo or in vitro, and the resulting TNFR protein variants. Such variants may be prepared by controlling the splicing of pre-mRNA molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 or 8 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 or 8 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has therapeutic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.
摘要翻译：本发明涉及用于在体内或体外制备TNFα受体（TNFR）的剪接变体的组合物和方法，以及所得的TNFR蛋白质变体。可以通过控制前mRNA分子的剪接和用剪接切换寡核苷酸或剪接切换寡聚体（SSO）调节蛋白质表达来制备这些变体。根据本发明的优选SSO靶向TNFR1（TNFRSF1A）或TNFR2（TNFRSF1A）前mRNA的外显子7或8，通常导致在部分或全部外显子7或8中包含缺失的TNFR变体的产生。发现针对外显子7的SSOs产生可溶形式的TNFR，其具有治疗炎性疾病的治疗益处。 SSO的特点是它们基本上无能力或不能招募RNaseH。

9. 发明授权

US08772427B2 Continuous counter-current organosolv processing of lignocellulosic feedstocks 有权
标题翻译：连续逆流有机溶剂处理木质纤维素原料
公开(公告)号：US08772427B2
公开(公告)日：2014-07-08
申请号：US13484003
申请日：2012-05-30
申请人： Christer Hallberg , Donald O'Connor , Michael Rushton , Edward Kendall Pye , Gordon Gjennstad , Alex Berlin , John Ross McLachlan , Raymond Ma
发明人： Christer Hallberg , Donald O'Connor , Michael Rushton , Edward Kendall Pye , Gordon Gjennstad , Alex Berlin , John Ross McLachlan , Raymond Ma
IPC分类号： C08H7/00
CPC分类号： B01D3/002 , B01D3/143 , B01D3/145 , B01D3/148 , C07H19/00 , C08H8/00 , C12M21/04 , C12M45/06 , C12M45/09 , C12P5/023 , C12P7/00 , C12P7/08 , C12P7/16 , C12P7/18 , C12P7/40 , C12P7/54 , C12P7/56 , C12P19/14 , Y02E50/10 , Y02E50/16 , Y02E50/343
摘要： A modular process for organosolv fractionation of lignocellulosic feedstocks into component parts and further processing of said component parts into one or more of a de-lignified cellulose stream, a sugar stream, small-chain alcohol streams and four structurally distinct classes of lignin derivatives. The modular process comprises a first processing module configured for digesting lignocellulosic feedstocks with an organic solvent thereby producing a cellulosic solids fraction and a liquid fraction, a second processing module configured for recovering small-chain alcohols and optionally a first class of lignin derivatives from the cellulosic solids fraction, a third processing module configured for recovering from the liquid fraction at least one of a second class and a third class of lignin derivatives or mixtures thereof, and waste stream comprising a fourth class of lignin derivatives. The fourth processing module may optionally recover the fourth class of lignin derivatives.
摘要翻译：用于将木质纤维素原料有机溶剂分馏成组分部分并将所述组分部分进一步加工成一种或多种脱木质纤维素流，糖流，小链醇流和四种结构不同类型的木质素衍生物的模块化方法。模块化方法包括第一处理模块，其被配置用于用有机溶剂消化木质纤维素原料，从而产生纤维素固体部分和液体部分，第二处理模块被配置用于从纤维素中回收小链醇和任选的第一类木质素衍生物固体部分，第三处理模块，其被配置用于从第二类和第三类木质素衍生物或其混合物中的至少一种液体馏分回收，以及包含第四类木质素衍生物的废物流。第四处理模块可任选地回收第四类木质素衍生物。

10. 发明申请

US20130137091A1 Methods And Compositions For Incorporating Nucleotides 有权
公开(公告)号：US20130137091A1
公开(公告)日：2013-05-30
申请号：US13305415
申请日：2011-11-28
申请人： Steven Gordon , Jerzy Olejnik
发明人： Steven Gordon , Jerzy Olejnik
IPC分类号： G01N21/64
CPC分类号： C07H19/00 , C12Q1/6869 , C12Q1/6874 , C12Q2535/101 , G01N21/05 , G01N21/6428 , G01N21/645 , G01N2021/0346 , G01N2021/058 , G01N2021/6417 , G01N2021/6419 , G01N2021/6421 , G01N2021/6439 , G01N2021/6441 , G01N2021/6471 , G01N2201/062 , G01N2201/0627 , G01N2201/12
摘要： The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式